^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2Rβ partial agonist

    Related drugs:
    Associations

    News

    Trials
    2ms
    STK-012-101: Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (clinicaltrials.gov)
    P1/2, N=364, Recruiting, Synthekine | Phase classification: P1 --> P1/2 | N=202 --> 364 | Trial completion date: Oct 2027 --> Jan 2029 | Trial primary completion date: Oct 2027 --> Jan 2029
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • STK-012
    almost4years
    Discovery of EPIM-001, a tumor targeted engineered IL2 with biased IL2Rβ agonist activities (AACR 2022)
    Furthermore, in the human breast cancer cell line MDA-MB-231, EPIM-001 showed stronger tumor growth inhibition compared to Keytruda. EPIM-001 is a promising immune modulating drug candidate that selectively activates CD8+ T cells and NK Cells with strong anti-tumor activity and safe profile for both immune checkpoint sensitive and insensitive PD-L1 positive tumors.
    Late-breaking abstract
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • EPIM-001